Basic Information
RNALocate ID: | RLID:11001980 |
RNA Symbol: | hsa-miR-193a-3p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-193a-3p |
RNA ID: | miRBase:MIMAT0000459 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23539611 |
Tissue/Cell Line: | Seminal plasma |
Method: | Microarray |
Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001854 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001855 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:11001973 | Exosome | Urine | 28246603 |
RLID:11001974 | Exosome | B cell line (Raji)|Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001975 | Exosome | Brain tissue | 23382797 |
RLID:11001976 | Exosome | Plasma | 23663360 |
RLID:11001977 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001978 | Exosome | Serum | 24683445 |
RLID:11001979 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11001981 | Microvesicle | Hepatoma cells | 23771658 |
RLID:11001982 | Microvesicle | Colon cancer cell line (LIM1863) | 25330373 |
RLID-D:11000102 | Exosome | Breast milk | |
RLID-D:11000387 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-193a-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-22928 |
MNDR | hsa-miR-193a-3p | Oral squamous cell carcinoma | MNDR-E-MI-22929 |
MNDR | hsa-miR-193a-3p | Medulloblastoma | MNDR-E-MI-22930 |
MNDR | hsa-miR-193a-3p | Small intestinal neuroendocrine tumor | MNDR-E-MI-22931 |
MNDR | hsa-miR-193a-3p | Ovarian clear cell carcinoma | MNDR-E-MI-22932 |
MNDR | hsa-miR-193a-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-22933 |
MNDR | hsa-miR-193a-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-22934 |
MNDR | hsa-miR-193a-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-22935 |
MNDR | hsa-miR-193a-3p | Her2-receptor positive breast cancer | MNDR-E-MI-22936 |
MNDR | hsa-miR-193a-3p | Breast cancer luminal a | MNDR-E-MI-22937 |
MNDR | hsa-miR-193a-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-22938 |
MNDR | hsa-miR-193a-3p | B cell acute lymphoblastic leukemia | MNDR-E-MI-22939 |
MNDR | hsa-miR-193a-3p | Neurofibromatosis 1 | MNDR-E-MI-22940 |
MNDR | hsa-miR-193a-3p | Small intestine cancer | MNDR-E-MI-22941 |
MNDR | hsa-miR-193a-3p | Prostate cancer | MNDR-E-MI-22942 |
MNDR | hsa-miR-193a-3p | Gastric cancer | MNDR-E-MI-22943 |
MNDR | hsa-miR-193a-3p | Alzheimer disease | MNDR-E-MI-22944 |
MNDR | hsa-miR-193a-3p | Dysautonomia familial | MNDR-E-MI-22945 |
MNDR | hsa-miR-193a-3p | Polycystic ovary syndrome | MNDR-E-MI-22946 |
MNDR | hsa-miR-193a-3p | Myotonic dystrophy | MNDR-E-MI-22947 |
MNDR | hsa-miR-193a-3p | Cardiovascular disease | MNDR-E-MI-22948 |
MNDR | hsa-miR-193a-3p | Lung cancer | MNDR-E-MI-22949 |
MNDR | hsa-miR-193a-3p | Parkinson disease | MNDR-E-MI-22950 |
MNDR | hsa-miR-193a-3p | Basal-like breast cancer | MNDR-E-MI-22951 |
MNDR | hsa-miR-193a-3p | Thyroid cancer | MNDR-E-MI-22952 |
MNDR | hsa-miR-193a-3p | Pituitary neoplasms | MNDR-E-MI-22953 |
MNDR | hsa-miR-193a-3p | Pancreatic cancer | MNDR-E-MI-22954 |
MNDR | hsa-miR-193a-3p | Nephroblastoma | MNDR-E-MI-22955 |
MNDR | hsa-miR-193a-3p | Colon cancer | MNDR-E-MI-22956 |
MNDR | hsa-miR-193a-3p | Ischemic attack transient | MNDR-E-MI-22957 |
MNDR | hsa-miR-193a-3p | Colon adenocarcinoma | MNDR-E-MI-22958 |
MNDR | hsa-miR-193a-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-22959 |
MNDR | hsa-miR-193a-3p | Familial ovarian cancer | MNDR-E-MI-22960 |
MNDR | hsa-miR-193a-3p | Acromegaly | MNDR-E-MI-22961 |
MNDR | hsa-miR-193a-3p | Prostate adenocarcinoma | MNDR-E-MI-22962 |
MNDR | hsa-miR-193a-3p | Carcinoma ductal breast | MNDR-E-MI-22963 |
MNDR | hsa-miR-193a-3p | Invasive ductal carcinoma | MNDR-E-MI-22964 |
MNDR | hsa-miR-193a-3p | Glioblastoma | MNDR-E-MI-22965 |
MNDR | hsa-miR-193a-3p | Astrocytoma | MNDR-E-MI-22966 |
MNDR | hsa-miR-193a-3p | Glioma | MNDR-E-MI-22967 |
MNDR | hsa-miR-193a-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-22968 |
MNDR | hsa-miR-193a-3p | Temporal lobe epilepsy | MNDR-E-MI-22969 |
MNDR | hsa-miR-193a-3p | Uterine cancer | MNDR-E-MI-22970 |
MNDR | hsa-miR-193a-3p | Cervical adenocarcinoma | MNDR-E-MI-22971 |
MNDR | hsa-miR-193a-3p | Gastric adenocarcinoma | MNDR-E-MI-22972 |
MNDR | hsa-miR-193a-3p | Cervical squamous cell carcinoma | MNDR-E-MI-22973 |
MNDR | hsa-miR-193a-3p | Pituitary adenoma | MNDR-E-MI-22974 |
MNDR | hsa-miR-193a-3p | Lung squamous cell carcinoma | MNDR-E-MI-22975 |
MNDR | hsa-miR-193a-3p | Carcinoma lung non-small-cell | MNDR-E-MI-22976 |
MNDR | hsa-miR-193a-3p | Thyroid carcinoma | MNDR-E-MI-22977 |
MNDR | hsa-miR-193a-3p | Papillary thyroid carcinoma | MNDR-E-MI-22978 |
MNDR | hsa-miR-193a-3p | Bladder urothelial carcinoma | MNDR-E-MI-22979 |
MNDR | hsa-miR-193a-3p | Pancreatic adenocarcinoma | MNDR-E-MI-22980 |
MNDR | hsa-miR-193a-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-22981 |
MNDR | hsa-miR-193a-3p | Carcinoma renal cell | MNDR-E-MI-22982 |
MNDR | hsa-miR-193a-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-22983 |
MNDR | hsa-miR-193a-3p | Clear cell renal cell carcinoma | MNDR-E-MI-22984 |
MNDR | hsa-miR-193a-3p | Cholangiocarcinoma | MNDR-E-MI-22985 |
MNDR | hsa-miR-193a-3p | Esophageal cancer | MNDR-E-MI-22986 |
MNDR | hsa-miR-193a-3p | Lung small cell carcinoma | MNDR-E-MI-22987 |
MNDR | hsa-miR-193a-3p | Synovial sarcoma | MNDR-E-MI-22988 |
MNDR | hsa-miR-193a-3p | T acute lymphoblastic leukemia | MNDR-E-MI-22989 |
MNDR | hsa-miR-193a-3p | Acute t cell leukemia | MNDR-E-MI-22990 |
MNDR | hsa-miR-193a-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-22991 |
MNDR | hsa-miR-193a-3p | Breast invasive carcinoma | MNDR-E-MI-22992 |
MNDR | hsa-miR-193a-3p | Hepatocellular carcinoma | MNDR-E-MI-22993 |
MNDR | hsa-miR-193a-3p | Familiar ovarian carcinoma | MNDR-E-MI-22994 |
MNDR | hsa-miR-193a-3p | Barrett's adenocarcinoma | MNDR-E-MI-22995 |
MNDR | hsa-miR-193a-3p | Hodgkin lymphoma | MNDR-E-MI-22996 |
MNDR | hsa-miR-193a-3p | Ulcerative colitis | MNDR-E-MI-22997 |
MNDR | hsa-miR-193a-3p | Burkitt lymphoma | MNDR-E-MI-22998 |
MNDR | hsa-miR-193a-3p | Tonsil cancer | MNDR-E-MI-22999 |
MNDR | hsa-miR-193a-3p | Degenerative disc disease | MNDR-E-MI-23000 |
MNDR | hsa-miR-193a-3p | Acute myelocytic leukemia | MNDR-E-MI-23001 |
MNDR | hsa-miR-193a-3p | Colorectal cancer | MNDR-E-MI-23002 |
MNDR | hsa-miR-193a-3p | Nasopharynx carcinoma | MNDR-E-MI-23003 |
MNDR | hsa-miR-193a-3p | Acute lymphocytic leukemia | MNDR-E-MI-23004 |
MNDR | hsa-miR-193a-3p | Esophageal squamous cell carcinoma | MNDR-E-MI-23005 |
MNDR | hsa-miR-193a-3p | Ependymoma | MNDR-E-MI-23006 |
MNDR | hsa-miR-193a-3p | Inflammation | MNDR-E-MI-23007 |
MNDR | hsa-miR-193a-3p | Nasopharyngeal cancer | MNDR-E-MI-23008 |
MNDR | hsa-miR-193a-3p | Pseudorabies | MNDR-E-MI-23009 |
MNDR | hsa-miR-193a-3p | Barrett's carcinogenesis | MNDR-E-MI-23010 |
MNDR | hsa-miR-193a-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-23011 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | CASC2 | Homo sapiens | RR00277759 |
TOP